Randomized crossover study· 2024

Cardiovascular and renal effects of apelin in chronic kidney disease

Chapman FA|Nyimanu D|Maguire JJ|Davenport AP|Webb DJ|Newby DE

Kidney International

PubMed
39402039
Evidence level
moderate
Verification
verified

Summary

A placebo-controlled crossover study evaluated pyr-apelin-13 in healthy participants and people with chronic kidney disease.

Limitations

Acute infusion|Small clinical study|No long-term outcomes|Specific stabilized endogenous isoform

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.